Frank Rahmani

FRANK RAHMANI focuses his practice on advising emerging growth companies and investors in the life sciences and technology industries. Working closely with founders, executives, boards of directors, investors and underwriters, Frank counsels clients in a broad range of matters, from formation and spinoff transactions, to financings and public offerings, governance, mergers and acquisitions, strategic collaborations and technology acquisition and licensing matters.

Frank has represented company clients, investors and underwriters in over five hundred financings and securities offerings ranging from venture financings to underwritten public offerings, and over one hundred strategic partnering, mergers and acquisitions and commercial transactions.

• Immunovant, a clinical stage biopharmaceutical company, on its common stock offerings with aggregate proceeds of US$550 million.
• Underwriters, including Goldman Sachs, Morgan Stanley and Citi, in connection with Klaviyo's initial public offering with aggregate proceeds of US$659 million and representation of underwriters in connection with follow-on secondary offerings with aggregate proceeds of over US$567 million.
• Pharvaris, a clinical stage biotechnology company, on its US$66 million Series B financing, and the underwriters in the US$190 million initial public offering and follow-on offerings of Pharvaris with aggregate proceeds of over US$500 million.
• Underwriters, including Goldman Sachs and Morgan Stanley, in connection with Contineum Therapeutics initial public offering with aggregate proceeds of over US$110 million.
• Contego Medical, a medical device company, in connection with a series of related agreements with Medtronic, a strategic investment, exclusive distribution agreement and an acquisition option agreement.
• Supira Medical, a developer of medical devices, on its preferred stock financings, raising over US$230 million in the aggregate.
• Outset Medical, a medical technology company, on its
  • US$125 million Series E financing.
  • US$278 million initial public offering.
  • US$577 million secondary and follow-on public offerings.
  • US$169 million PIPE/private placement.
• Morgan Stanley, Jefferies, and Cowen as the lead underwriters in the US$129.4 million initial public offering by Immuneering Corporation, a biopharmaceutical company, and representation of underwriters in follow-on underwritten offering of Immuneering with aggregate proceeds of over US$200 million.
• VERO Biotech, a medical technology company, on multiple preferred equity and debt financings raising over US$250 million.
• IO Biotech, a clinical-stage biopharmaceutical company, on its US$115.1 million initial public offering, subsequent US$75 million PIPE financing with participation by investors including Lundbeckfonden, Kurma, Vivo Capital, and Novo Holdings, and €57.5 million venture debt financing with the European Investment Bank.
• Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, on its US$72 million initial public offering and subsequent equity and venture debt financings with aggregate proceeds of over US$150 million.
• Pyxis Oncology, a clinical stage biotechnology company, on its US$168 million initial public offering and subsequent acquisition of Apexigen.
• Roche in its investment in Freenome, a multiomics platform based lifesciences company, with aggregate proceeds from Roche and other investors in excess of US$840 million.
• Close The Loop, an Australian publicly listed company, in its expansion and acquisition of US assets and entities, including ISP Tek Service and Captive Trading, and related financings.
• Akura Medical, Laza Medical, and Myra Vision, medical technology companies, on their preferred stock financing, raising US$60 million, US$36 million, and US$25 million, respectively.
• Atia Vision Inc., an ophthalmology focused company, in its US$42 million Series E financing led by Cormorant Asset Management with participation by The Capital Partnership, PA MedTech VC Fund, AMED Ventures, and Shifamed Angel investors.
• Venus Medtech (Hangzhou) Inc., a leading, innovative Chinese structural heart disease treatment company, in its acquisition of Cardiovalve Ltd., an Israel-based, transcatheter mitral and tricuspid valve treatment company, for aggregate consideration of up to US$300 million.
• Morgan Stanley, Jefferies, and Cowen as the lead underwriters in the US$129.4 million initial public offering by Immuneering Corporation, a biopharmaceutical company, and representation of underwriters in follow-on underwritten offering of Immuneering.
• The underwriters in the US$198.7 million initial public offering by Tyra Biosciences, Inc., a precision oncology company. BofA Securities, Jefferies, and Cowen acted as the joint book-running managers.
• Arvelle Therapeutics, a biotechnology company, on its
  • Formation and subsequent US$207 million combined equity and product financing.
  • Sale to Angelini Pharma for a total cash consideration of up to US$960 million.
• Tempest Therapeutics, Inc., a privately held, clinical-stage oncology company, in its merger (i.e. reverse merger) with Millendo Therapeutics, Inc., a public company, in an all-stock transaction with the combined company being listed on NASDAQ as Tempest Therapeutics.
• NuVera Medical, Inc., a medical technology company, in connection with its acquisition by Biosense Webster, part of the Johnson & Johnson family of companies.
• Immunovant, a clinical-stage biotechnology company, on its agreement to merge with Health Sciences Acquisition Corporation, a special purpose acquisition company, and subsequent US$139 million underwritten public offering.
• Axovant Gene Therapy on its US$362.3 million initial public offering and multiple follow-on public offerings. Axovant is a clinical-stage biotechnology company focused on the treatment of neurological and neuromuscular diseases.
• Dermavant, a biopharmaceutical company focused on dermatology, in its formation and acquisition of assets from GSK for total consideration of €250 million.
• Myovant Sciences on its formation and license transaction from Takeda and subsequent US$218 million initial public offering. Myovant Sciences is a biopharmaceutical company focused on the innovative treatment of women’s health diseases and other endocrine-related disorders.
• Urovant on its initial public offering of US$100 Million. Urovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
• Venus Medtech, a publicly listed medical technology company, on its acquisition of Keystone Heart, a medical device company developing and manufacturing cerebral embolic protection (CEP) devices, and multiple collaboration and minority investments, including strategic investment in Pi-Cardia Ltd.
• Vineti, a commercial stage cloud-based platform for cells and gene therapies, on multiple financings including its US$68 million Series C financing.
• CardioMEMS, a medical technology company that has developed a proprietary wireless sensing and communication technology, on its acquisition by St. Jude Medical for US$455 million.
• OnCore Biopharma on its merger with Tekmira Pharmaceuticals, initially valued at US$1.1 billion, to create a new company (Arbutus) focused on developing a cure for people with chronic hepatitis B virus.
• RFS Pharma on its merger with Cocrystal Pharma initially valued at US$800 million. Cocrystal Pharma is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.
• The underwriters on the US$102 million initial public offering of WAVE Life Sciences, a biotechnology company.
• Underwriters on Establishment Lab’s US$76.9 million initial public offering. Jefferies and Cowen and Company acted as the lead book-running managers.

Some of the matters above were handled prior to joining Sidley.